H.C. Wainwright downgraded Sutro Biopharma (STRO) to Neutral from Buy with a price target of $2, down from $12, after the company announced a ...

Oppenheimer downgraded Sutro Biopharma (STRO) to Perform from Outperform. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses.

Sutro Biopharma is undergoing a seismic shake-up—jettisoning its CEO, half of its workforce, its lead candidate and its manufacturing facility in a major bid to save cash. The almost 50% layoffs ...

Sutro Biopharma Inc (NASDAQ:STRO) has prioritized three wholly owned pre-clinical programs in its next-generation ADC pipeline, indicating a focused strategic direction. The company's cash runway ...

Sutro Biopharma (NASDAQ:STRO) said on Thursday that, under its portfolio review, the company has decided to advance its dual-payload ADC programs, while deprioritizing development of luveltamab ...

Sutro Biopharma (NASDAQ:STRO) fell ~14% in the premarket on Friday after the company announced its decision to deprioritize its studies into the antibody-drug conjugate luveltamab tazevibulin as ...

Jane Chung has replaced Bill Newell as Sutro's CEO. Antibody-drug conjugate (ADC) specialist Sutro Biopharma has shelved its lead drug for ovarian cancer and turned its attention to a trio of ...

Sutro Biopharma’s 2024 revenue fell to $62 million from $153.7 million in 2023. The company expects its cash runway to last through at least Q4 2026, excluding potential milestone payments. The ...

Sutro Biopharma will cut its workforce by half after completing a strategic review of the company's portfolio. Its top executive will also step down, as it switches focus to its next-generation ...

By 2026 Sutro also intends to progress its integrin beta-6 ADC, STRO-006, into clinical development and submit an IND for its first fully owned dual-payload ADC in 2027.By year-end, the firm will ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug ...

Sutro Biopharma, a South San Francisco company working to design anti-cancer drugs, is a fresh face for biotech’s extreme risk — and its fallout. As of this year, the Sutro company had ...